RAPP
Rapport Therapeutics, Inc. Common Stock · Healthcare · Biotechnology
Momentum-Eingaben (vergleichbare Manager):
Halterbreite +12.5% ·
Aktienfluss +3.6% ·
neue Nettopositionen +11.1%
— Formel
Breite Akkumulation — steigende Anteile bei mehr Haltern
Alle Eigentumszahlen: nur beobachtete 13F-Manager, Stammaktienpositionen, Berichtszeitraum Q2 2025
| Quartal | Inhaber | Δ | Aktien | Gemeldeter Wert | Neu | Ausstiege |
|---|---|---|---|---|---|---|
| Q2 2026 | 69 | +3 | 25.15M | $1.04B | +5 | −2 |
| Q1 2026 | 69 | +1 | 25.07M | $783.61M | +5 | −4 |
| Q4 2025 | 68 | +1 | 25.43M | $771.51M | +1 | — |
| Q3 2025 | 16 | +4 | 15.68M | $465.84M | +4 | — |
| Q2 2025 | 9 | +1 | 10.01M | $113.83M | +2 | −1 |
| Q1 2025 | 5 | 0 | 1.86M | $18.69M | +1 | −1 |
| Q4 2024 | 5 | 0 | 2.06M | $36.50M | — | — |
| Q3 2024 | 4 | -2 | 1.81M | $36.50M | +1 | −3 |
| Q2 2024 | 6 | — | 2.18M | $50.21M | — | — |
| # | Manager | Aktien | Δ Anteile | Wert | Deren Gewichtung | Gehalten | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 5.47M | — | $62.25M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Fidelity (FMR) ✦ | 5.47M | — | $62.25M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 1.53M | +42.1% | $17.35M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 1.53M | +42.1% | $17.35M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 5 | BlackRock ✦ (passiv) | 1.22M | — | $13.86M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | BlackRock ✦ (passiv) | 1.22M | — | $13.86M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | BlackRock ✦ (passiv) | 1.22M | — | $13.86M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | BlackRock ✦ (passiv) | 1.22M | — | $13.86M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | BlackRock ✦ (passiv) | 1.22M | — | $13.86M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | BlackRock ✦ (passiv) | 1.22M | — | $13.86M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | BlackRock ✦ (passiv) | 1.22M | — | $13.86M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | The Vanguard Group ✦ (passiv) | 1.11M | — | $12.59M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | The Vanguard Group ✦ (passiv) | 1.11M | — | $12.59M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | The Vanguard Group ✦ (passiv) | 1.11M | — | $12.59M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Geode Capital Management ✦ (passiv) | 333.16K | +5.5% | $3.79M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 16 | Geode Capital Management ✦ (passiv) | 333.16K | +5.5% | $3.79M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 17 | State Street Global Advisors ✦ (passiv) | 298.71K | +56.3% | $3.40M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 18 | Two Sigma Investments ✦ | 19.74K | -41.5% | $224,478 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 19 | AQR Capital Management ✦ | 16.97K | Neu | $192,971 | 0.0% | New | 1 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 16.97K | Neu | $192,971 | 0.0% | New | 1 | SEC ↗ |
| 21 | AQR Capital Management ✦ | 16.97K | Neu | $192,971 | 0.0% | New | 1 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 16.97K | Neu | $192,971 | 0.0% | New | 1 | SEC ↗ |
| 23 | Renaissance Technologies ✦ | 15.60K | Neu | $177,372 | 0.0% | New | 1 | SEC ↗ |
„Ihre Gewichtung" = Anteil der Position am gemeldeten 13F-Eigenkapitalwert des jeweiligen Managers — das Conviction-Maß. ✦ = kuratorisch ausgewählter Manager.
Neue Käufer
| AQR Capital Management | $192,971 | 0.0% |
| AQR Capital Management | $192,971 | 0.0% |
| AQR Capital Management | $192,971 | 0.0% |
| AQR Capital Management | $192,971 | 0.0% |
| Renaissance Technologies | $177,372 | 0.0% |
Ausgestiegen
| Citadel Advisors | $2.50M | war 0.0% |
Marktweiter Kontext: über ALLE 13F-Melder (strukturierte SEC-Daten, Q1 2026): 146 Inhaber, 52.47M Anteile, $1.59B gemeldet. Dies ist ein anderer, älterer Zeitraum als die oben genannten Zahlen des erfassten Universums; beide werden niemals vermischt.
Was die erfassten Halter dieses Wertpapiers am häufigsten sonst noch halten — Zählungen gemeinsamer Eigentümerschaft, keine fundamentalen Zusammenhänge.
Käufe auf dem offenen Markt (P)
Keine Insider-Käufe auf dem offenen Markt in unserem Erfassungszeitraum.
Verkäufe auf dem offenen Markt (S)
Officer · 404 Ant. · $20,160
Officer, Director · 3.66K Ant. · $171,837
Officer, Director · 19.50K Ant. · $936,846
Officer, Director · 5.79K Ant. · $281,721
Officer, Director · 14.17K Ant. · $651,492
Officer, Director · 8.37K Ant. · $391,280
Zuteilungen, Ausübungen und Steuereinbehalte werden hier nie als Käufe oder Verkäufe gezählt. Methodik